Business Wire

Clasp Therapeutics Presents Comprehensive Preclinical Data Validating First-in-Class Precision T Cell Engager Against p53 Mutant Solid Tumors at SITC Annual Meeting

CAMBRIDGE, MA. & ROCKVILLE, MD.--(BUSINESS WIRE)--Clasp Therapeutics, a biotechnology company bringing unparalleled precision to immuno-oncology using next-generation TCEs, today announced new data ...
C&EN

Clasp Therapeutics launches with $150 million in hand

Clasp Therapeutics, a company that aims to create a next-generation version of immunoncology drugs called bispecific T cell engagers (TCEs), launched today with $150 million in series A financing. The ...
Business Wire

Clasp Therapeutics Launches With $150 Million to Pioneer Precision Immuno-Oncology Using Next-Generation T Cell Engagers With Unparalleled Specificity

CAMBRIDGE, Mass. & ROCKVILLE, Md.--(BUSINESS WIRE)--Clasp Therapeutics, a biotechnology company bringing unparalleled precision to immuno-oncology using next-generation T cell engagers (TCEs), ...
FierceBiotech

Third Rock, Novo Holdings-backed Clasp Tx hooks $150M series A for next-gen cancer treatments

A new immuno-oncology biotech has emerged, clasping $150 million that will go toward developing next-generation T cell engagers (TCEs) targeting a range of hard-to-treat tumors. Clasp Therapeutics ...